Skip to main content
. 2023 Feb 20;201(1):57–63. doi: 10.1007/s00408-023-00603-z

Fig. 1.

Fig. 1

Proportions of patients in each disease cohort with T2Cs: a overall; b US; c EUR5. AD atopic dermatitis, AR allergic rhinitis, CRSwNP chronic rhinosinusitis with nasal polyps, EUR5 France, Germany, Italy, Spain, United Kingdom, M/S moderate-to-severe, T2C co-existing type 2 inflammatory disease, US United States